Abstract 1078TiP
Background
SNS-101 is a novel monoclonal antibody, selectively targeting the active/protonated form of V-domain Ig suppressor of T-cell activation (VISTA) found in the low pH of the tumor microenvironment. SNS-101 selectively binds with high affinity to VISTA at pH 6.0 and blocks the interaction between its receptor, the T-cell checkpoint P-selectin glycoprotein ligand-1. Based on preclinical data, SNS-101, either as monotherapy or in combination therapy with a PD-1 blocker, cemiplimab, is expected to exhibit an acceptable tolerability profile and demonstrate anti-tumor activity in pts with advanced solid tumors.
Trial design
This is a first in human, open-label, multi-center, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of SNS-101, as monotherapy or in combination with cemiplimab in pts with advanced solid tumors. This study is being conducted in 3 parts: Part A (∼25 pts): Phase 1 (P1) Monotherapy Dose Escalation (SNS-101 alone) Part B (∼24 pts): P1 Combination Dose Escalation (SNS-101 + cemiplimab) Part C (∼80 pts): Phase 2 (P2) Expansion Cohorts (SNS-101 ± cemiplimab) Dose escalation/de-escalation will proceed following the Bayesian Optimal Interval Design until the Maximum Tolerated Dose (MTD)/Recommended phase 2 Dose (RP2D) is determined. Tumor imaging will be performed every 6 weeks. All pts will receive SNS-101 ± cemiplimab as intravenous infusion(s) every 3 wks and may continue until confirmed progressive disease or unacceptable toxicity. Primary objectives include safety, tolerability and RP2D/MTD (P1); and to evaluate anti-tumor activity (P2). Key eligibility includes histologically or cytologically locally advanced, unresectable or metastatic solid tumor, measurable disease, Eastern Cooperative Oncology Group ≤1 and pre-treatment/on-treatment tumor biopsy samples. Tumor types for P2 will be determined based on data from P1 and emerging results from preclinical studies/scientific data. The IND cleared in April 2023 and the study is open for enrollment.
Clinical trial identification
SNS-101-2-1.
Editorial acknowledgement
Legal entity responsible for the study
Sensei Biotherapeutics.
Funding
Sensei Biotherapeutics.
Disclosure
K.P. Papadopoulos: Financial Interests, Personal, Advisory Board: Turning Point Therapeutics, Bicycle, Basilia; Financial Interests, Institutional, Full or part-time Employment: START; Financial Interests, Personal, Ownership Interest: START; Financial Interests, Institutional, Local PI, For conduct of clinical trial: 3D Medicines, AbbVie, ADC Therapeutics, Amgen, Anheart Therapeutics, Bayer, Daiichi Sankyo, EMD Serono, F-Star, Incyte, Jounce Therapeutics, Lilly, Linnaeus Therapeutics, Merck, Mersana, Mirati Therapeutics, Pfizer, Regeneron Pharmaceuticals, Revalution Medicines, Syros Pharmaceuticals, Tempest Therapeutics, Treadwell Therapeutics. S. Sen: Financial Interests, Personal, Steering Committee Member: Boehringer Ingelheim, Roche; Non-Financial Interests, Institutional, Principal Investigator: ABM Therapeutics, Boehringer Ingelheim, Centessa Pharmaceuticals, Ideaya Biosciences, OncoResponse, Parthenon Biotherapeutics, Pyxis Oncology, Sensei Biotherapeutics, Zentalis Pharmaceuticals. D. Smith: Financial Interests, Institutional, Full or part-time Employment: Sensei Bio; Financial Interests, Personal, Stocks/Shares: Sensei Bio. E. van der Horst: Financial Interests, Personal, Officer, CSO: Sensei Biotherapeutics; Financial Interests, Personal, Stocks/Shares, CSO: Sensei Biotherapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Presenter: Min Hee Hong
Session: Poster session 19
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19
1335P - Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
Presenter: Sonam Puri
Session: Poster session 19
1336P - Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Presenter: Felix Saalfeld
Session: Poster session 19
1337P - Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
Presenter: Lin Wu
Session: Poster session 19
1338P - Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Presenter: Bhumsuk Keam
Session: Poster session 19
1339P - Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
Presenter: Bivas Biswas
Session: Poster session 19
1340P - Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Presenter: Dongming Zhang
Session: Poster session 19
1341P - Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
Presenter: Panwen Tian
Session: Poster session 19
1342P - Effect of the timing of intervention in craniocerebral radiotherapy on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
Presenter: Guangchuan Deng
Session: Poster session 19